CeleCor Therapeutics

Executive Summary

CeleCor Therapeutics is a private biopharmaceutical company focused on developing zalunfiban, a next-generation, subcutaneously injected GPIIb/IIIa platelet inhibitor designed for pre-hospital treatment of ST-segment elevation myocardial infarction (STEMI) heart attacks. By enabling rapid administration before hospital arrival, zalunfiban aims to reduce time to platelet inhibition and improve outcomes in acute myocardial infarction, addressing a critical unmet need in emergency cardiovascular care. The company's lead asset is currently in clinical development, with prior studies demonstrating favorable pharmacokinetics and safety. If successful, zalunfiban could become a standard-of-care pre-hospital therapy, potentially competing with intravenous GPIIb/IIIa inhibitors and anticoagulants. As a private entity, CeleCor's valuation and funding history are undisclosed, but the firm's specialized focus on a single, high-impact indication positions it for potential strategic partnerships or acquisition upon positive data.

Upcoming Catalysts (preview)

• Q4 2026Phase 2/3 Trial Results for Zalunfiban in Pre-Hospital STEMI40% success
• Q2 2027Initiation of Pivotal Phase 3 Trial60% success
• Q3 2026Regulatory Guidance or FDA Meeting Outcome70% success